# To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

> **NCT05699408** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 513 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** INS068 injection
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT05699408
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-31
- **Primary completion:** 2024-11-23
- **Final completion:** 2024-11-23
- **Target enrollment:** 513 (ACTUAL)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05699408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05699408, "To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05699408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*